KemPharm Issues Letter to Shareholders marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
NKTR Teams Up With MRK, Pfizer Initiates Multiple Myeloma Trial, PCSA On Watch
KENILWORTH (NJ) (dpa-AFX) - Today s Daily Dose brings you news about Nektar s collaboration with Merck; Pfizer initiating a refractory multiple myeloma study; Processa Pharma s strategic financing; and vTv Therapeutics initiation of a phase 1 multiple ascending dose study of HPP737.
Read on.
1. Nektar Teams Up With Merck
Nektar Therapeutics (NKTR) has entered into a clinical trial collaboration and supply agreement with Merck (MRK) for a Phase 2/3 study of Bempegaldesleukin in combination with KEYTRUDA for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck.
Cannabis and hemp company
Jushi Holdings Inc. (CSE:JUSH) (OTCQB:JUSHF) is cutting the ribbon on its second store in Sauget, Illinois.
This is the company s 13th store the Boca Raton, Florida-based company opted to open in the country and third in the Prairie State.
BEYOND / HELLO Route 3 located at 1401 Mississippi Ave, Suite 17 is scheduled to start serving customers on Tuesday, Dec. 22.
Jushi CEO and chairman Jim Cacioppo (pictured) noted that the newest dispensary located in the heart of Metro East s nightlife would meet robust consumer demand for high-quality cannabis products in the state.
As of Monday, the company had around $91 million in cash and short-term investments. In addition, its total debt amounted to $93 million, excluding leases and property, as well as plant and equipment financing obligations.